[go: up one dir, main page]

WO2012151237A1 - Compositions de comprimés à dissolution rapide pour administration vaginale - Google Patents

Compositions de comprimés à dissolution rapide pour administration vaginale Download PDF

Info

Publication number
WO2012151237A1
WO2012151237A1 PCT/US2012/036055 US2012036055W WO2012151237A1 WO 2012151237 A1 WO2012151237 A1 WO 2012151237A1 US 2012036055 W US2012036055 W US 2012036055W WO 2012151237 A1 WO2012151237 A1 WO 2012151237A1
Authority
WO
WIPO (PCT)
Prior art keywords
agents
pharmaceutical composition
microgranules
group
rapid dissolve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/036055
Other languages
English (en)
Inventor
Gopi Venkatesh
Vijaya Swaminathan
Jin-Wang Lai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adare Pharma Solutions Inc
Original Assignee
Aptalis Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP12779335.4A priority Critical patent/EP2704694A4/fr
Priority to AU2012250862A priority patent/AU2012250862B2/en
Priority to KR1020137031788A priority patent/KR20140014264A/ko
Priority to KR1020167025256A priority patent/KR20160112012A/ko
Priority to MX2013012745A priority patent/MX2013012745A/es
Priority to NZ617376A priority patent/NZ617376B2/en
Priority to RU2013150323/15A priority patent/RU2013150323A/ru
Priority to AP2013007268A priority patent/AP2013007268A0/xx
Priority to SG2013080882A priority patent/SG194725A1/en
Application filed by Aptalis Pharmatech Inc filed Critical Aptalis Pharmatech Inc
Priority to CN201280026286.XA priority patent/CN103596556A/zh
Priority to JP2014509373A priority patent/JP6154803B2/ja
Priority to CA2839790A priority patent/CA2839790A1/fr
Publication of WO2012151237A1 publication Critical patent/WO2012151237A1/fr
Priority to IL229170A priority patent/IL229170A0/en
Priority to US14/069,712 priority patent/US20180177733A9/en
Anticipated expiration legal-status Critical
Priority to US15/879,806 priority patent/US20180147152A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • Vaginal drag delivery is a potential route for therapy via topical action or systemic absorption as well as uterine targeting of active pharmaceutical ingredients. It offers advantages such as:
  • Emulsion based vaginal drag delivery systems have been developed, such as ones containing (i) one or more globule stabilizing polymers (e.g., HP C, polyvinyl alcohol, or a PEGylatecl lipid) and (ii) a therapeutically active drug; drags approved for or used for the treatment, prophylaxis, cure, or mitigation of diseases of the vagina, urinary tract, cervix, or other female reproductive organ; inducement of contraception; or systemic drug therapy.
  • globule stabilizing polymers e.g., HP C, polyvinyl alcohol, or a PEGylatecl lipid
  • a therapeutically active drug e.g., a therapeutically active drug
  • US 20030180366 discloses a novel, microemuision based, essentially pH neutral, vaginal drug deliver ⁇ ' system suitable for modified deliveiy of a therapeutically active material in the vaginal cavity.
  • US 20050276836 discloses a method of coating a vaginal device for delivering therapeutic or health-promoting agents with a miicoadhesive compositio .
  • WO 2008133928 discloses a method of treating a patient having an epithelial lesion, such as of the vagina, or disorder of impaired mucin function as well as methods of treating pain associated with epithelial lesions and disorders of impaired mucin function using a pharmaceutical composition containing mucin glycoproteins in combination with therapeutic agents, e.g. , trefoil polypeptides.
  • WO 2010061284 discloses a controlled release, intravaginal, pharmaceutical dosage form consisting of at least, one pharmaceutically active ingredient which is admixed with a combination of biocompatible and biodegradable polymers and shaped for insertion into the vagina of a patient.
  • the present inventors surprisingly found a way to provide a vaginal dosage form, a 'rapid dissolve tablet formulation,' which promises to meet the unmet medical need for a vaginal dosage form that is easy to administer in privacy and which rapidly disintegrates/dissolves upon insertion into the vaginal cavity.
  • This dosage form creates a viscous suspension that is spread rapidly and widely over the vaginal mucosa, and is retained for a sufficiently long time to provide therapeutic efficacy via topical action or systemic absoiption.
  • use of a vaginal applicator is not required for these tablets, thereby making them an attractive dosage form based on potential reductions in packaging materials ⁇ i.e., increased portability) and manufacturing costs.
  • This dosage form may be used in the context of HI V therapy as well as other therapeutic applications.
  • antipyretics antispasmodics
  • anticholinergics anticholinergics
  • sympathomimetics antixanthine derivatives
  • the bioadhesive property of the polymer excipient e.g., low- substituted hydroxyethylcelluiose, hydroxypropylcellulose, hypromellose, polycarboxylic acids, polyvinylpyrrolidone, vinylpyrrolidone-polwinyl acetate copolymer, ethylene glycol 6000 - vinylcaprolactam - vinyl acetate copolymer, polyvinyl alcohol , polyethylene oxide, poly(lactic co-glycolic acid), polyaniide, alginic acid salts, carrageenan, chitosan, and cellulosic gum) will enhance bioadherence of the active ingredient (drug) to the mucosa surface, thereby increasing the retention time for improved therapy via topical action or systemic absorption.
  • the active ingredient drug
  • the present invention is related to a rapid dissolve tablet comprising rapidly dispersing microgranules comprising at least one sugar alcohol and at least one disintegrant.
  • This tablet may rapidly disintegrate upon insertion into the vagina of a patient, forming a viscous drug suspension that rapidly and widely spreads to coat the vaginal mucosa with the drug suspension/solution.
  • FIG. 1 shows a schematic of a 'Rapid Dissolve Tablet' as conceived in certain embodiments of the present invention.
  • FIG. 3 shows mean tenofovir plasma concentration - time profiles following a multi-dose (7 once-daily dosing) administration of tenofovir rapid dissolve tablets (RDTs) into the vagina, of female rabbits.
  • RDTs tenofovir rapid dissolve tablets
  • 'drug includes a pharmaceutically acceptable and therapeutically effective compound, pharmaceutically acceptable salts, stereoisomers and mixtures of stereoisomers, solvates (including hydrates), polymorphs, or prodrugs thereof.
  • pharmaceutically acceptable salts pharmaceutically acceptable salts, stereoisomers and mixtures of stereoisomers, solvates (including hydrates), polymorphs, or prodrugs thereof.
  • the reference encompasses the base drug, pharmaceutically acceptable salts, stereoisomers and mixtures of stereoisomers, solvates (including hydrates), polymorphs, or prodrugs thereof.
  • organic acids include amino acids, e.g. , the natural iy-occurring amino acids, lysine, arginine, glutamic acid, glycine, serine, threonine, alanine, isoleucine, leucine, etc.
  • suitable salts can be found in, e.g., S. M. Birge et at, J.
  • rapidly dissolve tablet refers to a tablet that disintegrates rapidly, such as in about 8 min, about 6 min, about 4 min, or about 2 mm, in the vaginal cavity of a patient after administration/insertion into the vaginal cavity.
  • the rate of disintegration can vary, but is slower than the rate of disintegration of orally disintegrating tablets, or faster than the rate of disintegration of conventional or bioadhesive vaginal tablets, when tested as described herein (e.g., the USP ⁇ 701> disintegration time test method).
  • patient compliance refers to non-adherence to dosing regimens by patients who are prescribed to follow a certain dosing regimen of a particular medication in need. Noncompliance or adherence to a dosing regimen is a major medical problem in the world costing billions of dollars and affecting lifestyles of millions of people.
  • antiviral agents analgesics; antitrichomonial agents; antiprotozoan agents; antim ooplasm agents; antireiroviral agents; nucleoside analogues; reverse transcriptase inhibitors; protease inhibitors; contraceptive agents; anorexics and appetite suppressants; steroids; anthelmintics; anesthetics; antiarthritics; antiasthma agents: anticonvulsants: antidepressants; antidiabetic agents; antidiarrheals; antihistamines; anti-inflammatory agents antimigraine preparations; antimotion sickness agents: antinauseants; antineoplastics; antiparkinsonism agents; antipruritics; antipsychotics: antipyretics; antispasmodics; anticholinergics: sympathomimetics; xanthine derivatives; cardiovascular preparations; calcium channel blockers; beta blockers;
  • the present invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising one or more drugs selected from the group of antiretroviral agents consisting of NRTls (e.g., apricitabiiie , eiitecavir, emtricitabine, tenofovir, abacavir, adefovir, their salts and mixtures thereof), NNRTIs (e.g., nevirapine, delavirdine, efavirenz, rilpivirine, UC-781 , MKC-442, quinoxaline HBY 097, DMP 266, their salts and mixtures thereof), protease inhibitors (e.g., indinavir, amprenavir, darunavir, lotinavir, nelfmavir, ritonavir, sequinavir, atazanavir, tipranavir, their salts and mixtures thereof), and integrase inhibitors (e.g., N
  • vaginal creams ointments, gels, inserts/rings, and tablets are currently available.
  • Dahl discloses in EP 1773296 the preparation of a pharmaceutical vaginal gel comprising tenofovir.
  • This dosage form may not benefit individuals with AIDS or those who want to avoid the risk of HIV transmission or infections during sexual activity, as the gel/applicator- like other similar gel formulations-may suffer from limitations such as leakage, messmess, and low residence time.
  • the present invention is directed to a pharmaceutical
  • composition in the form of rapid dissol ve microgranules or tablets comprising at least one drug suitable for vaginal administration selected from the group consisting of a bisphospbonate [e.g., alendronate, clodronate, etidronate, pamidronate, tiludronate, ibandronate, neridronate, risedronate, zoledronic acid, incadronate, minodronate, and olpadronate); an anti-migraine drug, such as one selected from the group consisting of ergotamine, dihydroergotamine, ergostine, butalbital, pheno barbital, acetaminophen, diclofenac sodium, ketoprofen, ketorolac, ibuprofen, piroxicam, naproxen, acetylsalicylic acid, flurbiprofen, tolfenamic acid, butorphanol,
  • a bisphospbonate e
  • meperidine methadone, sumatriptan, naratriptan, razatriptan, zoimitriptan, almotriptan, eletriptan, dexamethasone, hydrocortisone, isometheptene, chiorpromazine, diazepam, droperidol, valproic acid, gabapentin, topiramate and divalproex sodium; an anti-nausea drug, such as one selected from the group consisting of metoclopramide, prochlorperazine,
  • domperidone ondansetron, tropisetron, dolasetron, nabilone, dronabinol, ievonantradol. aprepitant, cyelizine, promethazine, sildenafil, oxytocin, oxytoci , oxybutynin, bromocriptine, rifamycin, azithromycin; steroids used in hormone replacement therapy or for contraception: calcitonin; LHRH and analogues; insulin; and human growth hormones, and combinations thereof.
  • the present invention is directed to a pharmaceutical composition in the form of rapid dissolve niicrogranules comprising at least one drug suitable for vaginal administration, at least, one sugar alcohol, such as mannitol or a saccharide such as lactose, and at least one polymeric binder such as low-substituted hydroxyethylcellulose.
  • a pharmaceutical composition in the form of rapid dissolve niicrogranules comprising at least one drug suitable for vaginal administration, at least, one sugar alcohol, such as mannitol or a saccharide such as lactose, and at least one polymeric binder such as low-substituted hydroxyethylcellulose.
  • Such compositions may be used, for example, for therapy via topical action or systemic absorption upon insertion of the medicinal composition into the vaginal cavity of a patient/subject in need thereof.
  • the pharmaceutical composition in the form of rapid dissolve microgranules further comprises at least one bioadhesive polymer, such as low-substituted hydroxyethylcellulose,
  • This bioadhesive polymer may be provided at a desired concentration, which may, upon forming a viscous drug-containing suspension in the vaginal cavity of a patient/subject, coat the vaginal mucosa, thereby improving its bioadherence and therapeutic efficacy via longer retention for topical action or systemic absorption.
  • sugar alcohols/saccharides include, but are not limited to, mannitol, sorbitol, xylitol, arabitol, erythritoL glycerol, hydro genated starch hydrolysate, isomalt, lactitol, lactose, maititol, sucrose, maltose, and combinations thereof.
  • disintegraiits include, but are not limited to crospovidone, sodium starch glycolate, starch, crosslinked sodium carboxymethylcellulose, low-substituted
  • the disintegrant can be present in the pharmaceutical composition in the form of rapid dissolve microgranules, for example, from about 1 % to about, 1 0%, from about 3% to about 7%, to about 5%, inclusive of all ranges and subranges there between.
  • bioadhesive polymers include, but are not limited to, hydroxypropylcelluiose, hypromellose, low-substituted hydroxyethylcellulose,
  • hydroxyethylethyleelluiose polycarboxylic acids, polyvinylpyrrolidone, vinylpyrrolidone- poly inyl acetate copolymer (e.g., Kollidon " VA 64 from. BASF), polyvinyl alcohol, polyethylene oxide, carbomers (CARBOPOL ® 974P, 941 , 940, 934, G70), poly(lactic co- glycolic acid), poiyamide, carrageenan, chitosan, and various cellulosic gums (e.g., xanthan gum).
  • polyvinylpyrrolidone vinylpyrrolidone- poly inyl acetate copolymer
  • polyvinyl alcohol polyethylene oxide
  • carbomers CARBOPOL ® 974P, 941 , 940, 934, G70
  • poly(lactic co- glycolic acid) poiyamide
  • carrageenan chitosan
  • various cellulosic gums e
  • the bioadhesive polymer can be present in the pharmaceutical composition in the form of rapid dissolve microgranules, from, for example, about 3% to about 10%, from about 4% to about 8%, to about 5%, inclusive of all ranges and subranges there between.
  • Non-limiting examples of suitable surfactants that may be employed include DL-alpha tocopherol, surfactants (e.g., CAPTEX 200, Tween 20, Tween 80, Vitamin E TPGS, Capryol 90, CREMOPi !OR EL, CARBMOL, PEG 400, lecithin, Brij 92, LABRASOL, triacetin, sodium lauryl sulfate, ethylene glycol monostearate, polysorbates and poloxamers* ' , GELIJCIRE ® , LABRAF1L ® , LABRASOL*, IMWITOR ® , sodium lauryl salicylate, sodium dodecyl sulfate), and mixtures thereof.
  • surfactants e.g., CAPTEX 200, Tween 20, Tween 80, Vitamin E TPGS, Capryol 90, CREMOPi !OR EL, CARBMOL, PEG 400, lecithin, Brij 92,
  • Non-limiting examples of suitable lipids that may be employed include lecithins;
  • a pharmaceutical composition in the form of a rapid dissolve tablet further comprises rapidly dispersing microgranules comprising a saccharide or a sugar alcohol in combination with a dismtegrant, produced in accordance with the specifications co-pending U.S. Patent Application Ser. No. 10/827,106 (published as US 2005/0232988).
  • the rapid dissolve tablet composition can further comprise rapidly dispersing microgran les comprising a sugar alcohol such as mannitol, a super dismtegrant such as low-substituted hydroxypropylcellulose, and an additive with multi-functionality of a binder and dismtegrant such as starch, modified starch and hydroxypropylcellulose.
  • a sugar alcohol such as mannitol
  • a super dismtegrant such as low-substituted hydroxypropylcellulose
  • an additive with multi-functionality of a binder and dismtegrant such as starch, modified starch and hydroxypropylcellulose.
  • Suitable disintegrants include, but, are not limited to, crospovidone, sodium starch glycolate, starch, crosslinked sodium carboxymethylceliulose, low-substituted
  • the ratio of the dismtegrant to the saccharide or sugar alcohol in the rapidly dispersing microgranules typically ranges from about 1 :99 to about 10:90, or from about 5:95 to about 10:90 on a weight basis and inclusive, of all ranges and subranges there between.
  • the disintegrant or the saccharide or sugar alcohol, or both are present in the form of particles having an average particle size of about 30 ⁇ or less in accordance with the specifications in co-pending U.S. Patent Application Ser. No. 10/827,106 (published as US 2005/0232988) and where the composition has a multifunctional additive the saccharide or sugar alcohol, are present in the form of particles having an average particle size of about 60 um or less.
  • the multifunctional additive may be present in the rapidly dispersing mierogranule composition at 1 -2,5% by weight, for example.
  • the ratio of the drug-containing granules to the rapidly disintegrating granules can range from about 5: 1 to about 2 :5, from about 3: 1 to about 1 :3, or from about 2: 2 to about 1 :2, or about 1: 1, inclusive of all ranges and subranges there between.
  • Disintegration of the RDTs of the invention is tested according to the USP ⁇ 701> Disintegration Test.
  • disintegration time of pharmaceutical compositions prepared as RDT tablets may be determined using a vaginal fluid stimulant prepared in accordance with the disclosure by Owen and Katz (Owen and Katz, 1999. Contraception. 59, 91 -95).
  • an RDT of the invention comprises a therapeutically effective amount of tenofovir, or pharmaceutically acceptable salts thereof, alone or in combination with emitricita ine at a ratio of from about 2: 1 to about 1 : 10, from about 1 : 1 to about 1 :8, or from about 1 :2 to about 1 :6, or about 2 :5.
  • the RDT substantially disintegrates in the vaginal cavity of a patient, forming a viscous, eas -to-spread suspension that spreads/coats the vaginal mucosa to provide efficacy via topical action or systemic absorption.
  • an RDT of the invention optionally includes a pharmaceutically acceptable bioadhesive polymer, such as one selected from the group consisting of low-substituted hydroxyethylcellulose,
  • vinylpyrrolidone-polyvinyl acetate copolymer e.g., ollidon* 1 VA 64 from BASF
  • an RDT weighs not less than about 50 mg; for example, 100 mg or more; 200 mg or more; 300 mg or more; or 500 mg or more. In some other embodiments, the RDT weighs not more than about 2000 mg; for example, 1600 mg or less: 1400 mg or less; 1200 mg or less; 1000 mg or less; 800 mg or less; or 500 mg or less. In another embodiment, the RDT weighs not more than about 800 mg. In another embodiment, the RDT weighs not more than about 600 mg. In another embodiment, the RDT weights not more than 500 mg.
  • the dosage forms of the invention can, for example, comprise two or more populations of antibiotic drug- containing particles, such as including at.
  • a dosage form can, for example, comprise a population of tenofovir, a nucleoside reverse transcriptase inhibitor, rapid dissolve particles as described herein, and in addition, a population of emitricitabine particles, for the prevention of AIDS.
  • a pharmaceutical composition of the present invention in the form, of a. rapid dissolve tablet for vaginal admin stration may comprise a therapeutically effective amount of propranolol, a non-selective beta blocker undergoing extensive first-pass (hepatic) metabolism upon oral administration, or pharmaceutically acceptable salt or a mixture thereof.
  • metronidazole and optionally an antibiotic selected from the group consisting of clarithromycin, sulfonamides, erythromycin, azithromycin, doxycycSine, quinofones, cefoxitin, ceftriaxone cifrofloxacin, doxyclycline, vancomycin, clindamycin, rifaximin, and metronidazole.
  • an antibiotic selected from the group consisting of clarithromycin, sulfonamides, erythromycin, azithromycin, doxycycSine, quinofones, cefoxitin, ceftriaxone cifrofloxacin, doxyclycline, vancomycin, clindamycin, rifaximin, and metronidazole.
  • a pharmaceutical composition of the present invention in the form of a rapid dissolve tablet for vaginal administration may comprise a therapeutically effective amount of clotrimazole, and optionally an antifungal agent selected from the group consisting of nystatin, ketoeonazole, itraconazole, and clotrimazole.
  • the present invention is directed to a method of preparing first a rapid dissolve rnicrogranule composition
  • a rapid dissolve rnicrogranule composition comprising at least one sugar alcohol, saccharide, or mixture thereof, a polymeric binder, optionally a super disintegrant or bioadhesive polymer, and a therapeutically effective amount of at least one drug selected from the group of
  • antiretroviral agents consisting of NRTls (e.g. , apricitabine , enteeavir, emtricitabine, tenofovir, ahacavir, adefovir, their salts and mixtures thereof), NNRTls (e.g., nevirapine, deiavirdine, efavirenz, UC-781 , MKC-442, quinoxaline HBY 097, DMP 266, their salts and mixtures thereof), protease inhibitors (e.g., indinavir, amprenavir, darunavir, lotinavir, nelfinavir, ritonavir, sequinavir, atazanavir, tipranavir, their salts and mixtures thereof), and integrase inhibitors (e.g., elvitegravir, MK-2048, their salts and mixtures thereof), next blending drug- containing rapid dissolve microgranules with rapidly dis
  • vaginal creams ointments, gels, inserts/rings, and tablets are currently available.
  • Dahl discloses in EP 1 773296 the preparation of a pharmaceutical vaginal gel comprising tenofovir.
  • This dosage form may not benefit individuals with AIDS or those who want to avoid the risk of HTV transmission or infections during sexual activity, as the gel/applicator-like other similar gel formulations-may suffer from limitations such as leakage, messiness, and low residence time.
  • the present invention is related to a method of preparing a rapid dissolve tablet composition
  • a rapid dissolve tablet composition comprising at least one sugar alcohol such as mannitol, a polymeric binder such as low-substituted hydroxypropyiceilulose, optionally a disintegrant such as crospovidone, and one NRTI alone, such as tenofovir or emtricitabine, or one or more NRTIs, such as tenofovir in combination with emtricitabine or dapivirene, and then form rapid dissolve tablets by compressing a formulation comprising said rapid dissolve microgranules, rapidly dispersing microgranules, macrocrystalline cellulose, a super disintegrant such as crospovidone, and a lubricant such as sodium stearyl fumarate on a rotary tablet press.
  • the granulation method is not limited; a fluid bed or high shear granulation method using a solution of a polymeric binder dissolved in purified water, ethanol, isopropanol, acetone, or a mixture thereof, is an embodiment of the present invention.
  • granulation may be performed by spraying a solution comprising a polymeric binder and a.
  • a top spray fluid bed granulator such as Glatt GPCG 3, GPCG 5, GPCG 120, or Fluid Air FA0300, and drying the granulation in the same fluid-bed dryer.
  • the granulation may also be performed using a high shear granulator, such as GMX 25 (batch size: 4-7 kg), GMX 65, or GMX 600 (batch size: 140- 160 kg) from Vector and drying in the Glatt.
  • the dried granulation thus produced may be sieved by passing through appropriate sieves to collect rapid dissolve drug-containing microgramiles with a desired particle size distribution by discarding fines and optionally milling resieving oversized granules.
  • the drug-containing microparticles granulated with one or more bioadhesive polymers to improve hioadherence characteristics to the vaginal mucosa may have a median particle size in the range of about 100-400 um. In some embodiments, not less than 90% of the microparticles are smaller than 600 pm for their incorporation into a rapid dissolve tablet.
  • the invention may be directed to a method of preparing a rapid dissolve tablet by blending rapid dissolve drug-containing microgramiles and rapidly dispersing microgranules prepared as described herein and compressing on a rotary tablet press into rapid dissolve tablets for administration into vaginal cavity of a patient in need of such a medication for therapeutic efficac via topical action or systemic absorption.
  • Lubricants such as magnesium stearate, calcium stearate, zinc stearate, stearic aid, sodium stearyl fumarate, glyceryl behenate, and the like may be used for lubricating the granules, or may be externally applied onto material contacting die and punch surfaces of a rotary tablet press used to compress tablets.
  • Sodium bicarbonate (54 g) is slowly added to purified water (2800 g) in a stainless steel container while continuously stirring to dissolve.
  • the pH of the bicarbonate solution is adjusted to about 6.0 if needed by adding hydrochloric acid, Hydroxypropylcellulose (Klucel LF; 12.5 g) is slowly added while stirring to dissolve; then tenofovir (180 g) is added to dissolve.
  • Preheated Glatt GPCG 3 equipped with top spray insert, granulation air distribution bottom plate, 200 mesh product retention screen, and 1 ,0 mm spray nozzle is charged with mannitol with an average particle size of less than 30 ⁇ (781 g) and crospovidone (60 g), both deagglomerated by passing through Comil.
  • the rapid dissolve micro granule composition is granulated while fluidizing the charge continuously and maintaining the process parameters at the following conditions: product temperature - 34.-i-.l°C; fiuidization air flow - 10 CFM; spray rate
  • the RD niicrograniiies are dried for a loss on drying to about 1 % by weight.
  • Sodium bicarbonate 54 g is slowly added to purified water (2500 g) in a stainless steel container while continuously stirring to dissolve.
  • the pH of the bicarbonate solution is adjusted to about 6.0 if needed by adding hydrochloric acid.
  • Low-substituted hydroxyethylcellulose 20 g is slowly added while stirring to dissolve: then tenofovir (180 g) is added to dissolve.
  • Preheated Glatt GFCG 3 is charged with deagglomerated mannitol (781 g) and crospovidone (60 g) and fluidized.
  • the RD microgranules are prepared by spraying the solution as disclosed in step Ex. I A above.
  • the disintegration times tested in accordance with USP method ⁇ 701 > for DT are 60-90 sec, 30-60 sec, and 30-60 sec, respectively for tenofovir RDT tablet batches of Formula Ex. I AD (TFV RDG: Ex. l A), Formula Ex. ! BD (TFV RDG: Ex. I B), and Formula Ex. 1 CD (TFV RDG: Ex. 1C).
  • RDTs of these formulations compressed at 4 kN are observed to disintegrate in 30-60 sec when tested by the USP method ⁇ 701 > and not less than 80% dissolved at 30 min when tested for dissolution in test tubes.
  • Sodium bicarbonate (54 g) is slowly added to a mixture of ethanol (540 g) and purified water (1260 g) in a stainless steel container while continuously stirring to dissolve.
  • the pH of the bicarbonate solution is measured to be about 6.1 5.
  • tenofovir (200 g) is added to dissolve followed by the addition of Low-substituted hydroxyethylcellulose (L-HEC; 30 g) to dissolve while stirring.
  • Preheated Glatt GPCG 3 is charged with deagglomerated mannitoi (1023 g) and fluidized.
  • the RD microgranules are prepared by spraying the solution as disclosed in step Ex.2B above. Upon completion of spraying, the loss on drying of RD microgranules is about 1 .5% by weight.
  • the objective of this study was to evaluate the pharmacokinetics of tenofovir after a single dose or seven daily doses when administered in rapid dissolve tablet form in female rabbits with a minimum body weight of 2.5 kg (n 6 in each group; blood sampled at 0, 0.5, 1 , 2, 4, 8, and 24 hrs post dosing day 1 or 7 in group 1 & 3 and at 0, 0.5, 1 .0, 1 .5, and 2 hrs post dosing day 1 or 7 in group 2 & 4).
  • acepromazine maleate 0.3- 0.5 mg/kg or to effect was administered via subcutaneous administration to mildly sedate the animal.
  • a single tablet was inserted into the abdominal vagina of each animal (approximately 8 cm) with an 18 catheter. No lubrication was used as this may affect tablet absorption, A detailed clinical examination of each animal was performed daily during the study. Observations included, but was not limited to, evaluation of the skin, fur, eyes, ears, nose, oral cavity, thorax, abdomen, external genitalia, limbs and feet, respiratory and circulatory effects, autonomic effects such as salivation, nervous system effects including tremors, convulsions, reactivity to handling, and atypical behavior.
  • Figure 2 shows the mean tenofovir plasma concentration - time profiles following insertion of a single tenofovir RDT (i.e. , RDTs of Ex. 2 CD) into the vaginal cavity of female rabbits while Figure 3 shows the corresponding tenofovir concentrations following multi-dose (7 once-daily dosing) administration.
  • Figure 4 shows the mean free and total tenofovir contents of the abdominal and vaginal tissues at 2 and 24 hrs pos dosing following insertion of a single tenofovir RDT into the vaginal cavity of female rabbits while Figure 5 shows the corresponding fenofovir concentrations following multi-dose (7 once-daily dosing) administration.
  • Figure 6 shows the mean predose and postdose tenofovir concentrations in eck-Cel ® at 2 and 24 hrs post dosing following insertion of a single tenofovir RDT into the vaginal cavity of female rabbits while Figure 7 shows the corresponding predose and postdose tenofovir concentrations in Weck-Cel ''8 ' following multi-dose (7 once-daily dosing) administration.
  • the contents of the product bowl are well mixed with the impeller speed set at 150 RPM for 2 minutes.
  • the powder mixture is granulated by spraying purified water at a spray rate of about 100 g/miri at. the following processing parameters: spray nozzle pore size - 0.085"; impeller setting: speed - 325 RPM, time
  • Preheated Glatt GPCG 3 is charged with deagglonierated mannitol (2737 g) and fiuidizcd.
  • the RD microgranules are prepared by spraying the solution at the following conditions: product support screen - 200 mesh; nozzle tip size - 1.2 mm;
  • the FTC RD microgranules are dried at the inlet air temperature set at 42°C for a. loss on drying to about 1% by weight.
  • compositions including the lubricant, sodium stearyl fumarate and are compressed (see Table 3 for compositions) on a Beta tablet press equipped with, partial tooling at a compression force of 4 - 6 kN and turret speed of 15 RPM. Samples are collected at the start, mid, and end of each run for testing for in-process tablet properties.
  • the Manesty Beta press equipped with eight (8) 12 mm round, lozenge tooling having no embossing is set. up to the following parameters for 40 mg TFV / 40 mg FCT RDTs:
  • Tablet weight total(l O) - 5.00 g; Nominal: 500 mg; Range: 460-540 mg
  • Main compression 3.3 mm (or 2.85 mm for TFV) Force feeder setting; 3.
  • the press was set to run at 25 rpm and after a few die table/turret rotations, 10 tablets are collected before stopping the press. Ten tablets are collected for determining the weight of 10 tablets and are inspected for tablet's appearance (picking, capping, etc).
  • the tablet press is adjusted, as necessary, in order to produce tablets that meet the specifications listed above for weight, thickness and hardness, and results are recorded on the production batch record. If required, the parameters are readjusted as necessary to produce tablets that meet the friability specifications listed above
  • Table 3 Compositions of RDTs (40 mg TFV; 40 mg FCT; 40 mg TFV/40 mg FCT;
  • Vinylpyrrolidone- vinyl acetate copolymer e.g., Kollidon ⁇ VA 64 from. BASF; 50 g
  • a mixture of ethanol and purified water in a stainless steel container while continuously stirring to dissolve.
  • metronidazole 180 g
  • Preheated Glatt GPCG 3 is charged with deagglomerated rnannitol (770 g) and crospovidone (50 g) and fiuidized.
  • the RD microgranules are prepared by spraying the solution at the following conditions: product temperature - 34 ⁇ 1°C; fluidization air flow - 4 CFM; spray rate - 8-12 mL/rain. Upon completion of spraying, the RD microgranules are dried for a loss on drying to about 1 % by weight.
  • Vinyipyrrolidone -polyvinyl acetate copolymer e.g., Kollidon*' VA 64 from BASF; 50 g
  • Vinyipyrrolidone -polyvinyl acetate copolymer e.g., Kollidon*' VA 64 from BASF; 50 g
  • propranolol HCI 240 g
  • Preheated Glatt GPCG 3 is charged with deagglomerated mannitol (560 g) and low-substituted hydroxyethylcellulose (50 g) and fluidized.
  • the RD microgranules are prepared by spraying the solution at the following conditions: product temperature - 38 ⁇ 2°C; fluidization air flow - 1 0 CFM; spray rate - 10-20 mL/min. Upon completion of spraying, the RD microgranules are dried for a loss on drying to about 1 % by weight.
  • RDT tablets (Formula Ex. 4 AD: Metronidazole RDTs, Formula Ex. 4BD: Clotrimazole RDTs, and Formula Ex. 4CD: Propranolol HCI RDTs) containing required amounts of

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

La présente invention concerne des compositions de comprimés vaginaux à dissolution rapide, de qualité pharmaceutique, qui comportent un ou plusieurs principes pharmaceutiques actifs, appropriés pour une thérapie par l'intermédiaire d'une action topique ou d'une absorption systémique. L'invention concerne également des procédés de fabrication et d'utilisation de telles compositions. Dans certains modes de réalisation, cette invention concerne des compositions pharmaceutiques qui comportent un ou plusieurs principes pharmaceutiques actifs, appropriés pour une voie d'administration vaginale, et des procédés de fabrication et d'utilisation de telles compositions pour une thérapie par l'intermédiaire d'une action topique ou d'une absorption systémique, ainsi que d'un ciblage utérin. Dans certains modes de réalisation, la présente invention concerne une composition pharmaceutique qui comporte un ou plusieurs principes pharmaceutiques actifs, appropriés pour une voie d'administration vaginale, un ou plusieurs excipients polymères ayant une double propriété d'action en tant que liant et matière bioadhésive, un ou plusieurs alcools de sucres ou saccharides et un ou plusieurs agents délitant.
PCT/US2012/036055 2011-05-02 2012-05-02 Compositions de comprimés à dissolution rapide pour administration vaginale Ceased WO2012151237A1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SG2013080882A SG194725A1 (en) 2011-05-02 2012-05-02 Rapid dissolve tablet compositions for vaginal administration
KR1020137031788A KR20140014264A (ko) 2011-05-02 2012-05-02 질내 투여용 속용성 정제 조성물
CN201280026286.XA CN103596556A (zh) 2011-05-02 2012-05-02 用于阴道给药的快速溶解片剂组合物
MX2013012745A MX2013012745A (es) 2011-05-02 2012-05-02 Composiciones en forma de comprmido de disolución rápida para administración vaginal.
NZ617376A NZ617376B2 (en) 2011-05-02 2012-05-02 Rapid dissolve tablet compositions for vaginal administration
RU2013150323/15A RU2013150323A (ru) 2011-05-02 2012-05-02 Композиции в форме быстрорастворимых таблеток для вагинального введения
AP2013007268A AP2013007268A0 (en) 2011-05-02 2012-05-02 Rapid dissolve tablet compositions for vaginal administration
EP12779335.4A EP2704694A4 (fr) 2011-05-02 2012-05-02 Compositions de comprimés à dissolution rapide pour administration vaginale
KR1020167025256A KR20160112012A (ko) 2011-05-02 2012-05-02 질내 투여용 속용성 정제 조성물
AU2012250862A AU2012250862B2 (en) 2011-05-02 2012-05-02 Rapid dissolve tablet compositions for vaginal administration
JP2014509373A JP6154803B2 (ja) 2011-05-02 2012-05-02 膣投与のための迅速溶解性錠剤組成物
CA2839790A CA2839790A1 (fr) 2011-05-02 2012-05-02 Compositions de comprimes a dissolution rapide pour administration vaginale
IL229170A IL229170A0 (en) 2011-05-02 2013-10-31 Preparations in the form of tablets that dissolve quickly for vaginal administration
US14/069,712 US20180177733A9 (en) 2011-05-02 2013-11-01 Rapid dissolve tablet compositions for vaginal administration
US15/879,806 US20180147152A1 (en) 2011-05-02 2018-01-25 Rapid dissolve tablet compositions for vaginal administration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161481582P 2011-05-02 2011-05-02
US61/481,582 2011-05-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/069,712 Continuation US20180177733A9 (en) 2011-05-02 2013-11-01 Rapid dissolve tablet compositions for vaginal administration

Publications (1)

Publication Number Publication Date
WO2012151237A1 true WO2012151237A1 (fr) 2012-11-08

Family

ID=47108022

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/036055 Ceased WO2012151237A1 (fr) 2011-05-02 2012-05-02 Compositions de comprimés à dissolution rapide pour administration vaginale

Country Status (16)

Country Link
EP (1) EP2704694A4 (fr)
JP (1) JP6154803B2 (fr)
KR (2) KR20160112012A (fr)
CN (1) CN103596556A (fr)
AP (1) AP2013007268A0 (fr)
AR (1) AR086249A1 (fr)
AU (1) AU2012250862B2 (fr)
CA (1) CA2839790A1 (fr)
CL (1) CL2013003161A1 (fr)
CO (1) CO6940408A2 (fr)
IL (1) IL229170A0 (fr)
MX (1) MX2013012745A (fr)
RU (1) RU2013150323A (fr)
SG (1) SG194725A1 (fr)
TW (1) TW201247240A (fr)
WO (1) WO2012151237A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015070072A1 (fr) * 2013-11-07 2015-05-14 Evofem, Inc. Procédés de fabrication de microbicides contraceptifs ayant des propriétés antivirales
WO2015095793A1 (fr) * 2013-12-19 2015-06-25 Evofem, Inc. Compositions et méthodes pour l'inhibition d'une inflammation et de maladies à l'aide d'un composé antimicrobien à base d'acide alginique
EP2968127A4 (fr) * 2013-03-15 2016-09-07 Conrad Préparations à faible taux de glycérol destinées au traitement et à la prévention du vih
JP2017510655A (ja) * 2014-04-11 2017-04-13 シノセラピューティクス インコーポレイテッドＳｉｎｏｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ポサコナゾール医薬組成物並びにその調製方法、使用及び医薬製剤
US9918702B2 (en) 2014-08-12 2018-03-20 Nextgen Jane, Inc. System and method for monitoring health based on collected bodily fluid
US11026883B2 (en) 2016-10-13 2021-06-08 Catalent U.K. Swindon Zydis Limited Lyophilized pharmaceutical compositions for vaginal delivery
US11253501B2 (en) 2015-06-01 2022-02-22 Lupin Inc. Secnidazole formulations and use in treating bacterial vaginosis
EP3870167A4 (fr) * 2018-10-23 2022-07-27 Eastern Virginia Medical School Compositions pharmaceutiques et procédés de préparation de formulations posologiques solides à la demande
US11419835B2 (en) 2016-10-04 2022-08-23 Evofem, Inc. Method of treatment and prevention of bacterial vaginosis
US11439610B2 (en) 2012-06-13 2022-09-13 Evofem, Inc. Compositions and methods for enhancing the efficacy of contraceptive microbicides
US11446011B2 (en) 2016-04-13 2022-09-20 Nextgen Jane, Inc. Sample collection and preservation devices, systems and methods
RU2810844C2 (ru) * 2018-07-31 2023-12-28 Мьюкоузе Инновейшнз, С.Л. Композиция для применения в предупреждении и/или лечении патологий слизистой оболочки мочеполовой системы

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104434992B (zh) * 2014-12-21 2018-06-08 昆明赛诺制药股份有限公司 一种美洲大蠊提取物生物粘附性阴道片及其制备方法
MX2020003660A (es) 2017-10-06 2020-08-03 Gedea Biotech Ab Derivados de acido gluconico para ser usados en el tratamiento y/o prevencion de infecciones microbianas.
WO2020128525A1 (fr) * 2018-12-21 2020-06-25 The University Of Liverpool Thérapies nrti
WO2020213983A1 (fr) * 2019-04-19 2020-10-22 한양대학교 산학협력단 Composition thermosensible contenant de l'acide phosphatidique et son utilisation

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159491A (en) * 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US20030180366A1 (en) 2002-03-20 2003-09-25 Kirschner Mitchell I. Bioadhesive drug delivery system
US20030215500A1 (en) 1996-06-14 2003-11-20 Motohiro Ohta Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US20040228932A1 (en) * 2003-05-12 2004-11-18 Pilgaonkar Pratibha S. Pharmaceutical excipient
US20050232988A1 (en) 2004-04-19 2005-10-20 Venkatesh Gopi M Orally disintegrating tablets and methods of manufacture
US20050276836A1 (en) 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
WO2006082596A2 (fr) 2005-01-19 2006-08-10 Kamalinder Kaur Singh Preparations contraceptives a base d'herbes
EP1773296A2 (fr) 2004-07-09 2007-04-18 Gilead Sciences, Inc. Formulations antivirales topiques
WO2007061529A1 (fr) * 2005-11-18 2007-05-31 Scidose Llc. Procede de lyophilisation et produits obtenus selon ledit procede
US20080166404A1 (en) * 2007-01-05 2008-07-10 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
WO2008148018A2 (fr) 2007-05-24 2008-12-04 New York Blood Center Inc. Comprimé vaginal rapidement dispersible qui fournit un gel bioadhésif
US20090169620A1 (en) * 2007-12-21 2009-07-02 Venkatesh Gopi M Orally disintegrating tablet compositions of temazepam
US20100040548A1 (en) * 2006-12-10 2010-02-18 Chongxi Yu High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds
US20110008454A1 (en) * 2002-03-06 2011-01-13 Universiteit Gent Immediate release pharmaceutical granule compositions and a continuous process for making them

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006022039A (ja) * 2004-07-08 2006-01-26 Towa Yakuhin Kk 高い安定性を有するシンバスタチン固形製剤
CN1257715C (zh) * 2004-08-02 2006-05-31 程月发 克林霉素甲硝唑阴道泡腾片及其制备方法和用途
CN1970079A (zh) * 2006-12-08 2007-05-30 陕西沃普森制药有限公司 重组人干扰素α2a阴道泡腾片及其制备方法
CN101283989A (zh) * 2008-02-28 2008-10-15 何文健 双唑泰阴道片制法及质量控制方法
CN101406463B (zh) * 2008-02-28 2012-04-25 陕西君碧莎制药有限公司 双唑泰阴道泡腾片及制备方法
KR20110073618A (ko) * 2008-10-23 2011-06-29 헨켈 코포레이션 탈분지 전분을 포함하는 질 펠렛
CN101780203B (zh) * 2010-03-16 2012-09-05 刘仁杰 滋阴暖巢香体葆春的润滑泡腾剂及其制备方法

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215500A1 (en) 1996-06-14 2003-11-20 Motohiro Ohta Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US20050276836A1 (en) 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6159491A (en) * 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
US20110008454A1 (en) * 2002-03-06 2011-01-13 Universiteit Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US20030180366A1 (en) 2002-03-20 2003-09-25 Kirschner Mitchell I. Bioadhesive drug delivery system
US6899890B2 (en) 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
US20040228932A1 (en) * 2003-05-12 2004-11-18 Pilgaonkar Pratibha S. Pharmaceutical excipient
US20050232988A1 (en) 2004-04-19 2005-10-20 Venkatesh Gopi M Orally disintegrating tablets and methods of manufacture
EP1773296A2 (fr) 2004-07-09 2007-04-18 Gilead Sciences, Inc. Formulations antivirales topiques
WO2006082596A2 (fr) 2005-01-19 2006-08-10 Kamalinder Kaur Singh Preparations contraceptives a base d'herbes
WO2007061529A1 (fr) * 2005-11-18 2007-05-31 Scidose Llc. Procede de lyophilisation et produits obtenus selon ledit procede
US20100040548A1 (en) * 2006-12-10 2010-02-18 Chongxi Yu High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds
US20080166404A1 (en) * 2007-01-05 2008-07-10 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
WO2008148018A2 (fr) 2007-05-24 2008-12-04 New York Blood Center Inc. Comprimé vaginal rapidement dispersible qui fournit un gel bioadhésif
US20090169620A1 (en) * 2007-12-21 2009-07-02 Venkatesh Gopi M Orally disintegrating tablet compositions of temazepam

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
BILENSOY ET AL., AAPS PHARMSCITECH., vol. 7, 2006, pages 19 - 29
BONFERONI ET AL., AAPS PHARM. SCITECH., vol. 7, 2006, pages E1 - E8
CESCHEL ET AL., DRUG DEL. IND. PHARM., vol. 6, 2001, pages 541 - 547
GARG ET AL., PHARMA. TECH., 2001, pages 14 - 23
LEHR, J. CONTROL. REL., vol. 65, 2000, pages 19 - 29
MANDAL ET AL., J. PHARM. BIOPHARM., vol. 50, 2000, pages 337 - 343
NDESENDO ET AL., INT. J. PHARM., vol. 370, 2009, pages 151 - 159
NEVES ET AL., EUR. J. PHARM. BIOPHARM., vol. 69, 2008, pages 622 - 632
OWEN; KATZ, CONTRACEPTION, vol. 59, 1999, pages 91 - 95
PERIOLI ET AL., INT. J. PHARM., vol. 377, 2009, pages 120 - 127
POELVOORDE ET AL., J. PHARM. BIOPHARM., vol. 71, 2009, pages 280 - 284,343
S. M. BIRGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
See also references of EP2704694A4
VALENTA, ADVANCED DRUG DEL. REV., vol. 57, 2005, pages 1692 - 1712
WANG ET AL., J. CONTR. REL., vol. 82, 2002, pages 39 - 50
YELLANKI ET AL., INT. J. PHARMTECH RES., vol. 2, 2010, pages 1746 - 1750

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11439610B2 (en) 2012-06-13 2022-09-13 Evofem, Inc. Compositions and methods for enhancing the efficacy of contraceptive microbicides
EP2968127A4 (fr) * 2013-03-15 2016-09-07 Conrad Préparations à faible taux de glycérol destinées au traitement et à la prévention du vih
WO2015070072A1 (fr) * 2013-11-07 2015-05-14 Evofem, Inc. Procédés de fabrication de microbicides contraceptifs ayant des propriétés antivirales
WO2015095793A1 (fr) * 2013-12-19 2015-06-25 Evofem, Inc. Compositions et méthodes pour l'inhibition d'une inflammation et de maladies à l'aide d'un composé antimicrobien à base d'acide alginique
RU2691950C1 (ru) * 2013-12-19 2019-06-19 Ивофем, Инк. Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты
US11337989B2 (en) 2013-12-19 2022-05-24 Evofem, Inc. Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
AU2020202835B2 (en) * 2013-12-19 2021-12-02 Evofem, Inc. Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
JP2017510655A (ja) * 2014-04-11 2017-04-13 シノセラピューティクス インコーポレイテッドＳｉｎｏｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ポサコナゾール医薬組成物並びにその調製方法、使用及び医薬製剤
US10022373B2 (en) 2014-04-11 2018-07-17 Sinotherapeutics Inc. Posaconazole pharmaceutical compositions and preparation methods, uses and pharmaceutical formulations thereof
US9918702B2 (en) 2014-08-12 2018-03-20 Nextgen Jane, Inc. System and method for monitoring health based on collected bodily fluid
US11253501B2 (en) 2015-06-01 2022-02-22 Lupin Inc. Secnidazole formulations and use in treating bacterial vaginosis
US11446011B2 (en) 2016-04-13 2022-09-20 Nextgen Jane, Inc. Sample collection and preservation devices, systems and methods
US11864740B2 (en) 2016-04-13 2024-01-09 Nextgen Jane, Inc. Sample collection and preservation devices, systems and methods
US12433573B2 (en) 2016-04-13 2025-10-07 Nextgen Jane, Inc. Sample collection and preservation devices, systems and methods
US11419835B2 (en) 2016-10-04 2022-08-23 Evofem, Inc. Method of treatment and prevention of bacterial vaginosis
RU2753864C2 (ru) * 2016-10-13 2021-08-24 Каталент Ю.Кей. Суиндон Зайдис Лимитед Лиофилизированные фармацевтические композиции для вагинальной доставки
US11026883B2 (en) 2016-10-13 2021-06-08 Catalent U.K. Swindon Zydis Limited Lyophilized pharmaceutical compositions for vaginal delivery
RU2810844C2 (ru) * 2018-07-31 2023-12-28 Мьюкоузе Инновейшнз, С.Л. Композиция для применения в предупреждении и/или лечении патологий слизистой оболочки мочеполовой системы
EP3870167A4 (fr) * 2018-10-23 2022-07-27 Eastern Virginia Medical School Compositions pharmaceutiques et procédés de préparation de formulations posologiques solides à la demande
US12370203B2 (en) 2018-10-23 2025-07-29 Eastern Virginia Medical School Pharmaceutical compositions and methods of making on demand solid dosage formulations
AU2019365204B2 (en) * 2018-10-23 2025-08-07 Eastern Virginia Medical School Pharmaceutical compositions and methods of making on demand solid dosage formulations

Also Published As

Publication number Publication date
AU2012250862B2 (en) 2015-07-09
KR20160112012A (ko) 2016-09-27
CO6940408A2 (es) 2014-05-09
NZ617376A (en) 2016-03-31
AR086249A1 (es) 2013-11-27
CA2839790A1 (fr) 2012-11-08
SG194725A1 (en) 2013-12-30
AP2013007268A0 (en) 2013-11-30
RU2013150323A (ru) 2015-06-10
KR20140014264A (ko) 2014-02-05
JP6154803B2 (ja) 2017-06-28
TW201247240A (en) 2012-12-01
EP2704694A4 (fr) 2014-11-19
MX2013012745A (es) 2014-12-05
CL2013003161A1 (es) 2014-08-01
EP2704694A1 (fr) 2014-03-12
CN103596556A (zh) 2014-02-19
AU2012250862A1 (en) 2013-05-02
IL229170A0 (en) 2013-12-31
JP2014513124A (ja) 2014-05-29

Similar Documents

Publication Publication Date Title
AU2012250862B2 (en) Rapid dissolve tablet compositions for vaginal administration
US20180147152A1 (en) Rapid dissolve tablet compositions for vaginal administration
KR102546742B1 (ko) 붕해가 개선된 경구용 고형 제제 조성물 및 이의 제조 방법
TWI583384B (zh) 包含４－胺基－５－氟－３－［６－（４－甲基哌嗪－１－基）－１ｈ－苯并咪唑－２－基］－１ｈ－喹啉－２－酮乳酸鹽單水合物之醫藥組合物
US10105365B2 (en) Solid antiviral dosage forms
KR20110089410A (ko) 구강 내 속붕괴성정 및 그의 제조 방법
JP2005506367A (ja) 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬
US9968607B2 (en) Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
JP6147711B2 (ja) 医薬用組成物及びその製造方法、並びに口腔内崩壊錠及びその製造方法
JP2014172855A (ja) 口腔内速崩壊性錠剤
US12370203B2 (en) Pharmaceutical compositions and methods of making on demand solid dosage formulations
NZ617376B2 (en) Rapid dissolve tablet compositions for vaginal administration
WO2024211882A1 (fr) Compositions stables de rilpivirine hcl en combinaison avec d'autres agents anti-retroviraux
JP5648265B2 (ja) 錠剤の製造方法
JP2016098230A5 (fr)
CA3228464A1 (fr) Compositions pharmaceutiques et methodes de traitement de l'hyperhidrose
Nath et al. A Review on Novel Formulation Approaches of Azidothymidine
NZ782840B2 (en) Melatonin mini-tablets and method of manufacturing the same
NZ782840A (en) Melatonin mini-tablets and method of manufacturing the same
CZ20002675A3 (cs) Tiagabinové prostředky s prodlouženým uvolňováním se sníženými vedlejšími účinky

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12779335

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2012250862

Country of ref document: AU

Date of ref document: 20120502

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014509373

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2839790

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/012745

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013003161

Country of ref document: CL

WWE Wipo information: entry into national phase

Ref document number: 2012779335

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20137031788

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13281162

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2013150323

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013028283

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112013028283

Country of ref document: BR

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: 112013028283

Country of ref document: BR